Insilico Medicine’s AI proposed a promising drug, but the patent for it names five human researchers.
A US appeals court has ruled that only human beings can be named as inventors on patents, even when an AI system generates the core idea. The decision emerged from a case involving an AI called DABUS and effectively blocks machines from receiving inventorship credit. Patent law requires an individual inventor, and the court determined that the plain meaning of individual is a human.
Insilico Medicine used its generative AI platform to propose a drug candidate for pulmonary fibrosis and touted the molecule as AI-discovered in a press release. When the company filed for a patent, however, it listed five human researchers, including CEO Alex Zhavoronkov, as inventors. The case highlights a gap between AI’s role in discovery and the legal framework that grants patent rights.
Builders and operators in AI-driven industries must ensure that a human meets the legal bar for inventorship on any patent application. If no human contributed enough, the patent could face an invalidity challenge and lose protection. The threat of invalidation may shape how companies document human involvement in AI-assisted research.
Ryan Abbott, the attorney behind the DABUS case, expects legal challenges to AI-generated drugs on the grounds of incorrect inventor listings. The larger open question is whether US policy will adapt to protect AI-generated discoveries without a human inventor. Courts and patent offices may need to reconcile rapid AI progress with statutes written for human inventors.
What matters
- Insilico Medicine named five humans, not its AI, as inventors on a drug patent for pulmonary fibrosis.
- Startups using AI for drug discovery must name a human inventor on every patent filing.
- Watch for court challenges to AI-generated drug patents on inventor eligibility.
Why it matters
Watch for court challenges to AI-generated drug patents on inventor eligibility.
This GenAI News article was prepared in original wording using reporting and materials published by MIT Technology Review AI. Source reference: https://www.technologyreview.com/2026/08/21/1142627/when-ai-designs-a-drug-who-gets-the-credit/.
Drafted by the GenAI News review pipeline.